Precision BioSciences, Inc.
DTILNASDAQHealthcare● Active
$6.87
+$0.10(+1.48%)
Market Cap$88129418
P/E Ratio—
52W High$8.82
52W Low$3.53
Precision BioSciences, Inc. (DTIL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DTIL · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $34.26M | $68.70M | $48.73M | $25.10M | $115.53M |
| Cost of Revenue | $2.75M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $31.51M | $68.70M | $48.73M | $25.10M | $115.53M |
| Gross Margin %(computed) | 91.97% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $54.17M | $59.56M | $53.38M | $46.12M | $115.24M |
| G&A Expenses | $32.24M | $35.30M | $39.09M | $41.28M | $39.67M |
| Total Operating Expenses | $83.66M | $94.86M | $92.46M | $87.41M | $154.91M |
| Operating Income | ($52.15M) | ($26.16M) | ($43.74M) | ($62.31M) | ($39.38M) |
| Operating Margin %(computed) | -152.19% | -38.08% | -89.76% | -248.26% | -34.08% |
| Interest Income | $4.24M | $6.76M | $7.69M | $3.47M | $0.21M |
| Interest Expense | $1.42M | $1.78M | $2.23M | $1.11M | $0.13M |
| Income Before Tax | ($46.61M) | $7.17M | ($42.53M) | ($72.91M) | ($30.60M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($46.61M) | $7.17M | ($61.32M) | ($111.64M) | ($30.60M) |
| Net Margin %(computed) | -136.03% | 10.43% | -125.84% | -444.80% | -26.49% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.63 | $1.05 | $-15.96 | $-38.10 | $-15.60 |
| Wtd Avg Shares | 12.83M | 6.83M | 3.84M | 2.93M | 1.96M |
| EBITDA | ($49.40M) | $13.53M | ($32.04M) | ($62.79M) | ($20.27M) |
| EBITDA Margin %(computed) | -144.16% | 19.69% | -65.76% | -250.20% | -17.55% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Precision BioSciences, Inc. data
About Precision BioSciences, Inc. (DTIL) Income Statement
Precision BioSciences, Inc. (DTIL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, DTIL reported revenue of $0.03B, gross profit of $0.03B (gross margin 91.97%), and net income of ($0.05B) — a net profit margin of -136.03%.
Frequently asked questions
DTIL · 4 questionsPrecision BioSciences, Inc. (DTIL) reported revenue of $0.03B for 2025, down 50.1% year-over-year.
DTIL revenueDTIL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09